Want to see HK:3332 full AI Analyst Report?
Top Page
Nanjing Sinolife United Co., Ltd. Class H
(3332)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$0.25
â–¼(-34.21% Downside)
Action:Reiterated
Date:09/24/26
The score is driven primarily by mid-range financial performance: strong revenue scale-up and high gross margin are offset by sharp post-2023 margin compression and uneven cash flow consistency. Technical signals are moderately positive (price above shorter-term averages with positive MACD), while valuation is supportive with a low P/E.
Positive Factors
Revenue Expansion
The multi-year revenue expansion indicates that the company has continued to grow its commercial base rather than relying only on a temporary boost. Sustained top-line progress can support operating scale, product investment, and broader earnings capacity over the next several quarters.
Negative Factors
Profitability Compression
The sharp decline in net and operating margins shows that revenue growth is currently translating into substantially less profit than at the 2023 peak. If this reset persists, it could limit internal funding, weaken returns on capital, and reduce the earnings benefit of further sales expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
The multi-year revenue expansion indicates that the company has continued to grow its commercial base rather than relying only on a temporary boost. Sustained top-line progress can support operating scale, product investment, and broader earnings capacity over the next several quarters.
Read all positive factors
Nanjing Sinolife United Co., Ltd. Class H (3332) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$341.85M
Dividend Yield2.82%
Average Volume (3M)131.27K
Price to Earnings (P/E)9.5
Beta (1Y)-0.32
Revenue Growth21.23%
EPS Growth24.06%
CountryHK
Employees533
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.02
Shares Outstanding946,298,340
10 Day Avg. Volume148,000
30 Day Avg. Volume131,266
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.77
Price to Sales (P/S)0.42
P/FCF Ratio4.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanjing Sinolife United Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Nanjing Sinolife United Company Limited functions as an investment holding entity primarily involved in the manufacturing, processing, and global distribution of nutritional supplements. Its operations span the People's Republic of China, Australi...
Nanjing Sinolife United Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
70
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 827.44M | 772.93M | 747.90M | 563.96M | 274.85M | 252.32M |
| Gross Profit | 626.68M | 566.18M | 538.27M | 379.66M | 160.00M | 138.80M |
| EBITDA | 34.83M | 31.77M | 48.19M | 75.08M | 4.88M | -13.49M |
| Net Income | 19.47M | 24.66M | 34.56M | 52.60M | -14.25M | -31.71M |
Balance Sheet | ||||||
| Total Assets | 695.27M | 603.72M | 505.56M | 505.42M | 436.99M | 390.11M |
| Cash, Cash Equivalents and Short-Term Investments | 309.78M | 240.36M | 104.53M | 122.79M | 78.19M | 76.23M |
| Total Debt | 191.24M | 107.24M | 33.90M | 35.16M | 35.75M | 8.87M |
| Total Liabilities | 278.30M | 186.58M | 111.46M | 127.35M | 113.19M | 59.87M |
| Stockholders Equity | 416.97M | 417.14M | 394.10M | 378.07M | 323.80M | 330.24M |
Cash Flow | ||||||
| Free Cash Flow | 51.84M | 64.92M | -6.65M | 44.76M | 4.05M | -9.68M |
| Operating Cash Flow | 56.45M | 68.63M | 957.00K | 47.11M | 7.92M | 421.00K |
| Investing Cash Flow | -1.89M | -725.00K | -6.00M | 449.00K | -3.47M | 1.52M |
| Financing Cash Flow | -50.59M | 11.84M | -4.53M | -4.50M | -4.08M | -4.45M |
Nanjing Sinolife United Co., Ltd. Class H Technical Analysis
Positive
0.38
Price Trends
0.15
Positive
0.17
Positive
0.27
Negative
Market Momentum
0.01
Negative
79.85
Negative
91.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3332, the sentiment is Positive. The current price of 0.38 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.15, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 79.85 is Negative, neither overbought nor oversold. The STOCH value of 91.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3332.
Nanjing Sinolife United Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$8.60B | 10.34 | 25.77% | 6.76% | 23.19% | -22.44% | |
69 Neutral | HK$341.85M | 9.47 | 4.67% | 2.82% | 21.23% | 24.06% | |
66 Neutral | HK$517.48M | 6.04 | 6.06% | 9.22% | 2.24% | -39.98% | |
65 Neutral | HK$22.82B | 7.91 | 10.98% | 8.22% | 2.19% | 10.78% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | HK$880.92M | -15.33 | -12.81% | 0.53% | 13.43% | 7.72% | |
46 Neutral | HK$12.82B | -138.41 | -1.21% | 4.86% | -2.44% | 81.73% |
* Consumer Defensive Sector Average
HK:3332
Nanjing Sinolife United Co., Ltd. Class H
0.23
-0.13
-36.67%
HK:1044
Hengan International Group Co
19.50
-4.33
-18.18%
HK:3828
Ming Fai International Holdings
0.71
-0.21
-23.20%
HK:0157
Natural Beauty Bio-Technology
0.44
-0.11
-20.00%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
20.78
-72.63
-77.75%
HK:6993
Blue Moon Group Holdings Ltd.
2.27
-0.80
-26.01%
Nanjing Sinolife United Co., Ltd. Class H Corporate Events
Nanjing Sinolife Overhauls Governance and Uses Reserves to Clear Parent Losses
Sep 4, 2026
Shareholders of Nanjing Sinolife United Company Limited approved, by unanimous poll at an extraordinary general meeting on 4 September 2026, significant amendments to the company’s Articles of Association, including the abolition of its boar...
Nanjing Sinolife United Delivers Strong Revenue Growth but Lower Profit in First Half 2026
Aug 24, 2026
Nanjing Sinolife United Company Limited, a PRC-incorporated health and nutrition group listed in Hong Kong, reported solid top-line growth for the six months ended 30 June 2026. The business continues to focus on wellness products for consumers, w...
Nanjing Sinolife United Calls EGM for Governance Overhaul and Loss Offset Plan
Aug 17, 2026
Nanjing Sinolife United Co., Ltd. has called an extraordinary general meeting to seek shareholder approval for significant amendments to its articles of association, including the abolition of its board of supervisors and the adoption of a new gov...
Nanjing Sinolife Schedules Board Meeting on Interim Results and Dividend
Aug 12, 2026
Nanjing Sinolife United Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 3332. Its board includes executive and independent non-executive directors, ...
Nanjing Sinolife Moves Oversight Powers to Audit Committee Under New PRC Company Law
Jul 30, 2026
Nanjing Sinolife United Co., Ltd. plans to amend its Articles of Association to align with the revised PRC Company Law and the China Securities Regulatory Commission’s updated guidelines for listed companies, effective from 2024 and 2025 res...
Nanjing Sinolife to Wipe Out RMB306 Million Losses Using Reserves
Jul 24, 2026
Nanjing Sinolife United Company Limited plans to use its capital reserve and statutory surplus reserve to eliminate accumulated losses of about RMB306 million recorded as of 31 December 2025. The reserves earmarked for this move, largely derived f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.